A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2

Frederick J Meyers, Carolyn Paradise, Sidney A Scudder, Gary Goodman, Michael Konrad

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


A more soluble formulation of recombinant interleukin-2 with a prolonged half-life would allow alternate routes or schedules of administration and enhance patient comfort. The covalent attachment of polyethylene glycol to recombinant interleukin-2 provides an analog with deal data suggesting those desired characteristics while maintaining biologic activity. This is the report of a phase 1 study in which we sought to determine the maximum tolerated dose of polyethylene glycol interleukin-2, observe biologic activity, and confirm the prolonged half-life in vivo. Sixty-six patients were entered into the study during 19 months. Polyethylene glycol interleukin-2 was administered intravenously once a week over 15 minutes. The maximum tolerated dose was 20 × 106 U/M2 The pattern of toxicity was quite similar to that of the parent compound. Four patients had evidence of tumor regression (three partial remission; one minor response). The pharmaeokinetic data confirmed a 10- to 20-fold prolongation in half-life compared with recombinant interleukin-2. No neutralizing antibodies were detected. This study provides sufficient impetus for the ongoing phase II studies of polyethylene glycol interleukin-2.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalClinical Pharmacology and Therapeutics
Issue number3
StatePublished - Mar 1991

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2'. Together they form a unique fingerprint.

Cite this